Special Survey of Production of Insulin Aspart Specific Antibody

Special Survey of Production of Insulin Aspart (IAsp) Specific Antibody

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01487369

Enrollment

204

Registered

2011-12-07

Start date

2002-04-30

Completion date

2009-10-31

Last updated

2016-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2

Brief summary

This study is conducted in Japan. The aim of this study is to collect data of production of insulin aspart specific antibody under normal clinical practice conditions.

Interventions

DRUGinsulin aspart

Injected subcutaneously (s.c., under the skin). Prescribed by physician as a result of normal clinical practice.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients with diabetes requiring insulin therapy

Exclusion criteria

* Patients who had a treatment history of NovoRapid® (insulin aspart)

Design outcomes

Primary

Measure	Time frame
Antibody titre findings	—

Secondary

Measure	Time frame
Hypoglycemic events	—
Adverse events	—
HbA1c (glycosylated haemoglobin)	—

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026